Cannabis Brands and China Challenges Cannabis brands account for a sizeable component of my law firm’s intellectual property work (and, indeed, our work generally). Historically, there has been little overlap between our cannabis and China practice areas, beyond our representing a number of cannabis ancillary product companies on their China manufacturing matters. This is starting to change,

The post Cannabis Brands and China: An Emerging IP Challenge appeared first on Harris Bricken Sliwoski LLP.

Unless you’ve been living under a rock, you know that a pretty historic announcement was made last week by the U.S. Department of Health and Human Services (HHS). HHS officially recommended that marijuana be rescheduled from Schedule I to Schedule III of the federal Controlled Substances Act (CSA). The HHS news means that the country’s top

The post Marijuana as Schedule III: Woe is Me? appeared first on Harris Bricken Sliwoski LLP.